This is a Phase 3b, open-label, multicenter study to evaluate the efficacy and safety of Glecaprevir (GLE)/Pibrentasvir (PIB) combination for an 8 or 12-week treatment duration in adults in Brazil with chronic hepatitis C virus (HCV) genotype (GT) 1 - 6 infection, without cirrhosis or with compensated cirrhosis, who are HCV treatment naïve.